Effects of GH and Lirglutide on AgRP
NCT05681299 on ClinicalTrials.gov · last registry update 2026-03-04
Recruiting now, toward 40 participants. Due to report 30 April 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: AgRP change in GH vs. placebo arms. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 May 2023 — 3 years so far.
- Status
- RECRUITING
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Columbia University
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2023-05-01
- Primary completion
- 2028-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
AgRP change in GH vs. placebo arms
Conditions studied
Healthy · Growth Hormone Deficiency
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.